UY39171A - Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta - Google Patents
Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de estaInfo
- Publication number
- UY39171A UY39171A UY0001039171A UY39171A UY39171A UY 39171 A UY39171 A UY 39171A UY 0001039171 A UY0001039171 A UY 0001039171A UY 39171 A UY39171 A UY 39171A UY 39171 A UY39171 A UY 39171A
- Authority
- UY
- Uruguay
- Prior art keywords
- solvate
- hydrate
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title abstract 2
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- RRMJMHOQSALEJJ-UHFFFAOYSA-N N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide Chemical compound CN(C)CC=1C(=NN(C=1)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC)C1=CC=CC=C1 RRMJMHOQSALEJJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009623P | 2020-04-14 | 2020-04-14 | |
| US202063014277P | 2020-04-23 | 2020-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39171A true UY39171A (es) | 2021-10-29 |
Family
ID=75562794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039171A UY39171A (es) | 2020-04-14 | 2021-04-13 | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12138351B2 (https=) |
| EP (1) | EP4135669A1 (https=) |
| JP (2) | JP7787824B2 (https=) |
| KR (1) | KR20230002656A (https=) |
| CN (1) | CN115484937A (https=) |
| AU (2) | AU2021257662B2 (https=) |
| CA (1) | CA3180184A1 (https=) |
| IL (1) | IL297240A (https=) |
| MX (1) | MX2022012898A (https=) |
| PH (1) | PH12022552454A1 (https=) |
| UY (1) | UY39171A (https=) |
| WO (1) | WO2021209893A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| WO2022253261A1 (zh) * | 2021-06-01 | 2022-12-08 | 杭州领业医药科技有限公司 | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 |
| CN118251220A (zh) * | 2022-01-19 | 2024-06-25 | 江苏奥赛康药业有限公司 | 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| AU2024337472A1 (en) | 2023-09-05 | 2026-04-16 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6437006B1 (en) * | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
| US6399591B1 (en) | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
| US7998505B2 (en) | 2006-10-27 | 2011-08-16 | Fmc Corporation | Dry granulation binders, products, and use thereof |
| EP2198857A1 (en) * | 2008-12-19 | 2010-06-23 | Ratiopharm GmbH | Oral dispersible tablet |
| ES2713330T3 (es) | 2009-12-11 | 2019-05-21 | Sumitomo Dainippon Pharma Co Ltd | Comprimido recubierto en seco que se desintegra oralmente |
| HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
| MX361088B (es) | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| WO2015006752A1 (en) * | 2013-07-12 | 2015-01-15 | The Regents Of The University Of California | Combination therapies for malaria |
| SMT202100205T1 (it) | 2013-12-12 | 2021-07-12 | Almirall Sa | Composizioni farmaceutiche comprendenti dimetil fumarato |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| HUE054848T2 (hu) | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| SG11201808626WA (en) | 2016-04-07 | 2018-10-30 | Chemocentryx Inc | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| US11198731B2 (en) * | 2017-01-20 | 2021-12-14 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
| EP3592338A1 (en) * | 2017-03-08 | 2020-01-15 | ARIAD Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| MY201038A (en) | 2017-07-28 | 2024-01-31 | Yuhan Corp | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same |
| WO2019022486A1 (en) | 2017-07-28 | 2019-01-31 | Yuhan Corporation | NOVEL INTERMEDIATES USEFUL FOR SYNTHESIZING AMINOPYRIMIDINE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND PROCESS FOR PREPARING AMINOPYRIMIDINE DERIVATIVES THEREWITH |
| SG11201913517UA (en) | 2017-07-28 | 2020-02-27 | Yuhan Corp | Improved process for preparing aminopyrimidine derivatives |
| CN110580014B (zh) * | 2018-06-11 | 2021-03-30 | 北京京东尚科信息技术有限公司 | 用于控制自动导引运输车的方法、装置和系统 |
| CN113164971A (zh) | 2018-07-20 | 2021-07-23 | 英默里斯美国公司 | 从铸造用砂废弃物中回收砂、膨润土和有机物 |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| US12576033B2 (en) | 2019-04-11 | 2026-03-17 | Gfb (Abc), Llc | Spray-dried formulation of a pyridazinone TRPC5 inhibitor |
| WO2020211915A1 (en) | 2019-04-17 | 2020-10-22 | Nordiccan A/S | Fast disintegrating cannabinoid tablets |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| CN119909073A (zh) | 2019-07-31 | 2025-05-02 | 豪夫迈·罗氏有限公司 | 新型药物制剂 |
-
2021
- 2021-04-13 US US17/228,753 patent/US12138351B2/en active Active
- 2021-04-13 IL IL297240A patent/IL297240A/en unknown
- 2021-04-13 PH PH1/2022/552454A patent/PH12022552454A1/en unknown
- 2021-04-13 CN CN202180028642.0A patent/CN115484937A/zh active Pending
- 2021-04-13 JP JP2022562451A patent/JP7787824B2/ja active Active
- 2021-04-13 KR KR1020227039484A patent/KR20230002656A/ko active Pending
- 2021-04-13 CA CA3180184A patent/CA3180184A1/en active Pending
- 2021-04-13 UY UY0001039171A patent/UY39171A/es unknown
- 2021-04-13 MX MX2022012898A patent/MX2022012898A/es unknown
- 2021-04-13 WO PCT/IB2021/053035 patent/WO2021209893A1/en not_active Ceased
- 2021-04-13 EP EP21719733.4A patent/EP4135669A1/en active Pending
- 2021-04-13 AU AU2021257662A patent/AU2021257662B2/en active Active
-
2024
- 2024-11-07 US US18/939,761 patent/US20250177311A1/en active Pending
-
2025
- 2025-05-09 AU AU2025203347A patent/AU2025203347A1/en active Pending
- 2025-08-22 JP JP2025138920A patent/JP2025179094A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025179094A (ja) | 2025-12-09 |
| AU2021257662B2 (en) | 2025-06-12 |
| PH12022552454A1 (en) | 2024-02-05 |
| MX2022012898A (es) | 2023-01-24 |
| CN115484937A (zh) | 2022-12-16 |
| WO2021209893A1 (en) | 2021-10-21 |
| JP7787824B2 (ja) | 2025-12-17 |
| AU2021257662A1 (en) | 2022-12-15 |
| IL297240A (en) | 2022-12-01 |
| US20210322323A1 (en) | 2021-10-21 |
| BR112022020609A2 (pt) | 2022-11-29 |
| CA3180184A1 (en) | 2021-10-21 |
| AU2025203347A1 (en) | 2025-05-29 |
| WO2021209893A8 (en) | 2022-10-13 |
| KR20230002656A (ko) | 2023-01-05 |
| TW202207940A (zh) | 2022-03-01 |
| US20250177311A1 (en) | 2025-06-05 |
| JP2023522634A (ja) | 2023-05-31 |
| US12138351B2 (en) | 2024-11-12 |
| EP4135669A1 (en) | 2023-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39171A (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta | |
| JOP20230113A1 (ar) | مشتقات ثلاثية الكربوكساميد كمثبطات prmt5 | |
| JOP20220282A1 (ar) | مركبات مفيدة لتثبيط كيناز ret | |
| BRPI1011657A2 (pt) | derivados aminopropiônicos substituídos como inibidores de neprilisina | |
| ECSP11011561A (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| AR117655A1 (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal | |
| RU2011138962A (ru) | Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1 | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| CY1111442T1 (el) | Ενωσεις πιπεριδινης και χρησεις αυτων | |
| BR112013031121A2 (pt) | composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento | |
| CY1111102T1 (el) | 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| JOP20220281A1 (ar) | مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| SA523442503B1 (ar) | مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| BRPI0620239B8 (pt) | derivados de 2-feniletilamino. | |
| AR121828A1 (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato o solvato de esta | |
| EA200970570A1 (ru) | Макролидные соединения, обладающие противовоспалительной активностью | |
| BR112023018766A2 (pt) | Moduladores alostéricos negativos de ciclopental[c]pirrol de nr2b | |
| MX2021014544A (es) | Derivados de aminoglucosidos antibacterianos. | |
| AR132113A1 (es) | Forma sólida de derivados de pirrolidona como activador de glucoquinasa | |
| NO20073031L (no) | Anvendelse av substistuerte cyklopropansyrederivater for fremstilling av medikamenter for anvendelse i behandlingen av metabolisk syndrom | |
| UY28095A1 (es) | Composición farmacéutica |